Referred to the House Committee on Energy and Commerce.
The bill requires HHS to update the National Action Plan for Adverse Drug Event Prevention to incorporate pharmacogenomics, convene the Federal Interagency Steering Committee, and report to Congress. It directs HHS to issue provider guidance on pharmacogenomic testing and to improve electronic health records and FDA adverse event reporting to capture drug-gene and drug-drug-gene information.
Liberals focus on patient-safety gains and demand funding, privacy safeguards
Relative to its intended legislative type, this bill is a well-scoped administrative measure that leverages existing authorities and directs specific reporting and guidance actions to incorporate pharmacogenomics into adverse drug event prevention and health IT workflows.
The bill requires HHS to update the National Action Plan for Adverse Drug Event Prevention to incorporate pharmacogenomics, convene the Federal Interagency Steering Committee, and report to Congress.
It directs HHS to issue provider guidance on pharmacogenomic testing and to improve electronic health records and FDA adverse event reporting to capture drug-gene and drug-drug-gene information.
The bill also directs a GAO study on including drug-gene information on drug labels and an HHS report on EHR improvements to support pharmacogenomic real-world evidence.
Technocratic, low‑salience improvements to drug safety and EHRs with limited fiscal asks increase plausibility, though implementation costs and stakeholder resistance create uncertainty.
Relative to its intended legislative type, this bill is a well-scoped administrative measure that leverages existing authorities and directs specific reporting and guidance actions to incorporate pharmacogenomics into adverse drug event prevention and health IT workflows. It assigns clear responsibilities and timelines for multiple deliverables and includes a GAO study and required reports to Congress.
Liberals focus on patient-safety gains and demand funding, privacy safeguards
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals focus on patient-safety gains and demand funding, privacy safeguards
Generally supportive: sees the bill as advancing precision medicine and preventing adverse drug events for patients.
Will push for protections, equitable access, and funding for implementation and coverage.
Some benefits (access, privacy protections) are speculative and depend on later rules.
Cautiously favorable: recognizes potential patient-safety gains and better surveillance, but worries about costs, timelines, and operational burdens.
Will seek clearer cost estimates, phased implementation, and measurable outcomes.
Skeptical: views this as an expansion of federal influence into clinical IT and practice standards, imposing regulatory and cost burdens.
May accept limited, voluntary measures if privacy and provider flexibility are ensured.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technocratic, low‑salience improvements to drug safety and EHRs with limited fiscal asks increase plausibility, though implementation costs and stakeholder resistance create uncertainty.
The bill has not accumulated any surfaced votes yet.
Liberals focus on patient-safety gains and demand funding, privacy safeguards
Technocratic, low‑salience improvements to drug safety and EHRs with limited fiscal asks increase plausibility, though implementation costs…
Relative to its intended legislative type, this bill is a well-scoped administrative measure that leverages existing authorities and directs specific reporting and guidance actions to incorporate pharmacogenomics into a…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.